BioLineRx Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the t… Read more
Market Cap & Net Worth: BioLineRx Ltd (BLRX)
BioLineRx Ltd (NASDAQ:BLRX) has a market capitalization of $11.55 Million ($11.55 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26725 globally and #9010 in its home market, demonstrating a 2.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioLineRx Ltd's stock price $2.71 by its total outstanding shares 4262685 (4.26 Million).
BioLineRx Ltd Market Cap History: 2015 to 2026
BioLineRx Ltd's market capitalization history from 2015 to 2026. Data shows change from $83.12 Million to $11.55 Million (-18.64% CAGR).
Index Memberships
BioLineRx Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #709 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2274 of 3165 |
Weight: BioLineRx Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioLineRx Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioLineRx Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
BioLineRx Ltd's market cap is 0.03 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $6.69 Million | $4.80 Million | -$60.61 Million | 1.39x | N/A |
| 2024 | $912.21K | $28.94 Million | -$9.22 Million | 0.03x | N/A |
Competitor Companies of BLRX by Market Capitalization
Companies near BioLineRx Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to BioLineRx Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BioLineRx Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, BioLineRx Ltd's market cap moved from $83.12 Million to $ 11.55 Million, with a yearly change of -18.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.55 Million | -2.17% |
| 2025 | $11.81 Million | +1194.39% |
| 2024 | $912.21K | -86.37% |
| 2023 | $6.69 Million | +166.10% |
| 2022 | $2.51 Million | -71.08% |
| 2021 | $8.70 Million | -19.05% |
| 2020 | $10.74 Million | +12.00% |
| 2019 | $9.59 Million | -65.70% |
| 2018 | $27.96 Million | -59.88% |
| 2017 | $69.69 Million | +18.48% |
| 2016 | $58.83 Million | -29.23% |
| 2015 | $83.12 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BioLineRx Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.55 Million USD |
| MoneyControl | $11.55 Million USD |
| MarketWatch | $11.55 Million USD |
| marketcap.company | $11.55 Million USD |
| Reuters | $11.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.